Barclays PLC Iovance Biotherapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 604,584 shares of IOVA stock, worth $4.46 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

604,584

Previous 604,584 -0.0%

Holding current value

$4.46 Million

Previous $5.68 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$7.28 - $11.9 $2.39 Million - $3.91 Million	328,284 Added 118.81%	604,584 $5.68 Million
Q2 2024 Aug 14, 2024	BUY	$7.78 - $14.19 $162,967 - $297,237	20,947 Added 8.2%	276,300 $2.22 Million
Q1 2024 May 15, 2024	SELL	$7.59 - $17.47 $4.41 Million - $10.1 Million	-580,822 Reduced 69.46%	255,353 $3.78 Million
Q4 2023 Feb 15, 2024	BUY	$3.3 - $8.89 $258,139 - $695,411	78,224 Added 10.32%	836,175 $6.8 Million
Q3 2023 Nov 07, 2023	BUY	$4.44 - $8.79 $1.01 Million - $2.01 Million	228,359 Added 43.12%	757,951 $3.45 Million
Q2 2023 Aug 03, 2023	BUY	$5.36 - $9.06 $602,635 - $1.02 Million	112,432 Added 26.95%	529,592 $3.73 Million
Q1 2023 May 04, 2023	SELL	$5.53 - $8.22 $1.18 Million - $1.76 Million	-213,790 Reduced 33.88%	417,160 $2.55 Million
Q4 2022 Feb 13, 2023	BUY	$5.62 - $10.0 $1.35 Million - $2.4 Million	240,344 Added 61.53%	630,950 $4.03 Million
Q3 2022 Nov 03, 2022	BUY	$9.53 - $13.11 $3.31 Million - $4.55 Million	347,191 Added 799.7%	390,606 $3.74 Million
Q2 2022 Aug 12, 2022	SELL	$6.38 - $18.33 $190,436 - $547,132	-29,849 Reduced 40.74%	43,415 $479,000
Q1 2022 May 16, 2022	BUY	$12.38 - $19.1 $833,322 - $1.29 Million	67,312 Added 1130.91%	73,264 $1.22 Million
Q4 2021 Feb 14, 2022	SELL	$16.55 - $27.63 $412,723 - $689,036	-24,938 Reduced 80.73%	5,952 $114,000
Q3 2021 Nov 09, 2021	SELL	$20.35 - $26.63 $1.21 Million - $1.58 Million	-59,373 Reduced 65.78%	30,890 $761,000
Q2 2021 Aug 13, 2021	BUY	$16.33 - $33.07 $357,120 - $723,207	21,869 Added 31.98%	90,263 $2.35 Million
Q1 2021 May 13, 2021	BUY	$28.67 - $52.59 $52,208 - $95,766	1,821 Added 2.74%	68,394 $2.17 Million
Q4 2020 Feb 11, 2021	BUY	$28.04 - $50.26 $213,580 - $382,830	7,617 Added 12.92%	66,573 $3.09 Million
Q3 2020 Nov 12, 2020	SELL	$27.75 - $36.3 $3.7 Million - $4.84 Million	-133,423 Reduced 69.35%	58,956 $1.94 Million
Q2 2020 Aug 12, 2020	BUY	$27.21 - $41.0 $1.92 Million - $2.89 Million	70,563 Added 57.93%	192,379 $5.28 Million
Q1 2020 May 13, 2020	SELL	$19.54 - $38.85 $1.72 Million - $3.41 Million	-87,865 Reduced 41.9%	121,816 $3.65 Million
Q4 2019 Feb 10, 2020	BUY	$17.95 - $29.41 $1.87 Million - $3.06 Million	104,169 Added 98.73%	209,681 $5.8 Million
Q3 2019 Nov 14, 2019	BUY	$17.99 - $26.0 $550,098 - $795,028	30,578 Added 40.81%	105,512 $1.92 Million
Q2 2019 Aug 14, 2019	BUY	$9.78 - $24.52 $184,900 - $463,575	18,906 Added 33.74%	74,934 $1.84 Million
Q1 2019 May 15, 2019	BUY	$8.41 - $11.26 $471,195 - $630,875	56,028 New	56,028 $534,000
Q4 2018 Feb 14, 2019	SELL	$7.51 - $11.93 $359,428 - $570,969	-47,860 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$11.25 - $17.7 $392,017 - $616,774	34,846 Added 267.76%	47,860 $539,000
Q2 2018 Aug 14, 2018	SELL	$12.45 - $16.95 $52,875 - $71,986	-4,247 Reduced 24.6%	13,014 $167,000
Q1 2018 May 15, 2018	SELL	$8.1 - $19.5 $150,157 - $361,491	-18,538 Reduced 51.78%	17,261 $291,000
Q4 2017 Feb 14, 2018	BUY	$6.65 - $9.25 $216,543 - $301,207	32,563 Added 1006.27%	35,799 $286,000
Q3 2017 Nov 14, 2017	BUY	$4.45 - $8.55 $14,400 - $27,667	3,236	3,236 $25,000

Others Institutions Holding IOVA

# of Institutions

313

Shares Held

237M

Call Options Held

3.77M

Put Options Held

1.7M

View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.16B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

More about IOVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account